Biocon Ltd. on Saturday said the U.S. health regulator has issued four observations after inspecting its Bengaluru-based active pharmaceutical ingredient facility.
The US Food and Drug Administration conducted a surveillance inspection of the API facility (Site 2), located at Bengaluru from September 23- 27, 2024, the company said in a regulatory filing.
'Four observations were cited at the end of the inspection, which the company will be addressing within the stipulated time,' it added.
The company does not foresee any impact on the business, Biocon said.
ADVERTISEMENT
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
RCB Announces Rs 25 Lakh Compensation To Families Of Stampede Victims
Aug 30, 2025
Bengaluru Traffic Police Announce 50% Rebate On Pending Fines: Dates, Eligibility, Payment Options
Aug 22, 2025
Trump Tariff Impact: Auto To Pharma—Fitch Flags Sectors Under 'Risk' Over 50% Tariff Rate
Aug 19, 2025
Biocon Q1 Results: Profit Slumps 95% Even As Revenue Rises
Aug 07, 2025
POPULAR
1
Stock Market LIVE: GIFT Nifty Hints At Positive Open; Brigade Enterprises, Mazagon Dock, H.G. Infra In Focus
2
Stock Market Today: All You Need To Know Going Into Trade On Sept. 1
3
India Hopes For Fair Elections In Myanmar: PM Modi To Myanmar's Junta Chief
4
Stocks To Watch Today: RBL Bank, Ola Electric, PNB Housing, HG Infra, NHPC, Hindustan Copper
5